[go: up one dir, main page]

BRPI0413667A - Processo para a preparação de 4-amino-3-carbonitrilas de quinolina - Google Patents

Processo para a preparação de 4-amino-3-carbonitrilas de quinolina

Info

Publication number
BRPI0413667A
BRPI0413667A BRPI0413667-5A BRPI0413667A BRPI0413667A BR PI0413667 A BRPI0413667 A BR PI0413667A BR PI0413667 A BRPI0413667 A BR PI0413667A BR PI0413667 A BRPI0413667 A BR PI0413667A
Authority
BR
Brazil
Prior art keywords
amino
quinoline
carbonitrile
cyanoacetamide
combining
Prior art date
Application number
BRPI0413667-5A
Other languages
English (en)
Inventor
Karen Wiggins Sutherland
Gregg Brian Feigelson
Diane Harris Boschelli
David Michael Blum
Henry Lee Strong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34215972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413667(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0413667A publication Critical patent/BRPI0413667A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE 4-AMINO-3-CARBONITRILAS DE QUINOLINA". A presente invenção refere-se a um processo para a preparação de uma 4-amino-3-carbonitrila de quinolina, que compreende combinar um composto amina com um ácido cianoacético e um catalisador ácido para obter uma cianoacetamida; condensar a cianoacetamida com uma anilina opcionalmente até tetrassubstituída em um solvente alcoólico e um ortoformiato de trialquila para produzir uma 2-amino-2-cianoacrilamida; combinar a 3-amino-2-cianoacrilamida com oxicloreto de fósforo em acetonitrila, butironitrila, tolueno ou xileno, opcionalmente em presença de um catalisador para produzir uma 4-amino-3-carbonitrila de quinolina e igualmente descreve um processo para a preparação de uma 7-amino-tieno¢3,2-b!piridina-6-carbonitrila compreendendo combinar um 3-amino tiofeno com uma cianoacetamida e ortoformiato de trialquila em um solvente alcoólico para obter uma 3-amino-2-cianoacrilamida; e combinar a 3-amino-2-cianoacrilamida com oxicloreto de fósforo e acetonitrila, butironitrila, tolueno ou xileno, opcionalmente em presença de um catalisador para produzir uma 7-aminotieno¢3,2-b!piridina-6-carbonitrila e igualmente descreve um processo para a preparação de uma 4 amino-3-carbonitrila de quinolina compreendendo combinar um composto amina com ácido cianoacético e um reagente de acoplamento peptídico para obter uma suspensão, filtrar a suspensão; para obter cianoacetamida; condensar a clanoacetamida com uma anilina opcionalmente até tetrassubstituída com um solvente alcoólico para obter uma 4-amino-3-carbonitrila de quinolina, e a invenção descreve um processo para obter uma cianoacetamida.
BRPI0413667-5A 2003-08-19 2004-08-13 Processo para a preparação de 4-amino-3-carbonitrilas de quinolina BRPI0413667A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49619103P 2003-08-19 2003-08-19
PCT/US2004/026329 WO2005019201A2 (en) 2003-08-19 2004-08-13 Process for the preparation of 4-amino-3-quinolinecarbonitriles

Publications (1)

Publication Number Publication Date
BRPI0413667A true BRPI0413667A (pt) 2006-10-24

Family

ID=34215972

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413667-5A BRPI0413667A (pt) 2003-08-19 2004-08-13 Processo para a preparação de 4-amino-3-carbonitrilas de quinolina

Country Status (25)

Country Link
US (2) US7297795B2 (pt)
EP (1) EP1660453A2 (pt)
JP (1) JP2007502819A (pt)
KR (1) KR20060066733A (pt)
CN (1) CN1835923A (pt)
AR (1) AR045277A1 (pt)
AU (1) AU2004267061A1 (pt)
BR (1) BRPI0413667A (pt)
CA (1) CA2535385A1 (pt)
CO (1) CO5670369A2 (pt)
CR (1) CR8226A (pt)
EC (1) ECSP066384A (pt)
GT (1) GT200400165A (pt)
IL (1) IL173456A0 (pt)
MX (1) MXPA06001590A (pt)
MY (1) MY140542A (pt)
NO (1) NO20060539L (pt)
PA (1) PA8609301A1 (pt)
PE (1) PE20050344A1 (pt)
RU (1) RU2345069C2 (pt)
SA (1) SA04250258B1 (pt)
SG (1) SG145744A1 (pt)
SV (1) SV2005001855A (pt)
TW (1) TW200517378A (pt)
WO (1) WO2005019201A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479561B2 (en) 2004-08-16 2009-01-20 Wyeth 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
SI1848414T1 (sl) 2005-02-03 2011-08-31 Gen Hospital Corp Postopek za zdravljenje raka, odpornega na gefitinib
AU2006247520A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same
RU2007140957A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
CN101180269A (zh) * 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
AU2006249600A1 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
CA2613053C (en) * 2005-07-01 2015-11-24 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
CN101378758A (zh) * 2006-02-08 2009-03-04 惠氏公司 经由钯介导的偶联反应制备7-烯基-3氰基喹啉
CN101195578B (zh) * 2006-12-08 2012-04-25 上海睿智化学研究有限公司 1-(卤烷氧基)-2-烷氧基-5-硝基苯类化合物的合成方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090312360A1 (en) 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP4218760A3 (en) 2009-04-06 2023-08-16 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
EP2448563A2 (en) 2009-07-02 2012-05-09 Wyeth LLC 3-cyanoquinoline tablet formulations and uses thereof
CN101792416B (zh) * 2010-01-15 2011-10-05 南京医科大学 一种博舒替尼的制备工艺
RS55783B1 (sr) * 2010-06-23 2017-07-31 Hanmi Science Co Ltd Novi derivati fuzionisanog pirimidina za inhibiciju aktivnosti tirozin kinaze
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
CN104876865A (zh) * 2014-02-27 2015-09-02 南京正荣医药化学有限公司 一种博舒替尼的制备工艺
CN107922390B (zh) 2015-07-06 2019-05-10 吉利德科学公司 Cot调节剂及其使用方法
EA201792612A1 (ru) 2015-07-06 2018-07-31 Джилид Сайэнс, Инк. 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CA3029457A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
JP2020537650A (ja) * 2017-10-18 2020-12-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． チロシンキナーゼ阻害剤の調製方法およびその中間体
CN108084085B (zh) * 2017-12-28 2019-11-26 山东铂源药业有限公司 一种n-(3-氯-4-(2-吡啶甲氧基)苯基)-2-氰基乙酰胺的制备方法
WO2019186429A1 (en) * 2018-03-30 2019-10-03 Sun Pharmaceutical Industries Limited A process for the preparation of bosutinib
CN109180578B (zh) * 2018-10-19 2020-06-26 山东创新药物研发有限公司 一种博舒替尼的制备方法
CN111646939A (zh) * 2019-03-04 2020-09-11 鲁南制药集团股份有限公司 一种博舒替尼的制备方法
CN111646955B (zh) * 2019-03-04 2024-05-24 鲁南制药集团股份有限公司 一种制备博舒替尼中间体的方法
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN115397511A (zh) 2020-03-30 2022-11-25 吉利德科学公司 Cot抑制剂化合物(s)-6-(((1-(双环[1.1.1]戊-1-基)-1h-1,2,3-三唑-4-基)2-甲基-1-氧代-1,2-二氢异喹啉-5-基)甲基)))氨基8-氯-(新戊基氨基)喹啉-3-甲腈的固体形式
CN115397824B (zh) 2020-04-02 2024-10-22 吉利德科学公司 用于制备cot抑制剂化合物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція

Also Published As

Publication number Publication date
SV2005001855A (es) 2005-11-04
MY140542A (en) 2009-12-31
MXPA06001590A (es) 2006-05-19
JP2007502819A (ja) 2007-02-15
WO2005019201A3 (en) 2005-08-04
ECSP066384A (es) 2006-08-30
GT200400165A (es) 2005-04-12
PE20050344A1 (es) 2005-06-19
AU2004267061A1 (en) 2005-03-03
WO2005019201A2 (en) 2005-03-03
NO20060539L (no) 2006-02-13
SA04250258B1 (ar) 2009-01-07
CR8226A (es) 2008-08-21
US20050043537A1 (en) 2005-02-24
KR20060066733A (ko) 2006-06-16
PA8609301A1 (es) 2005-03-03
TW200517378A (en) 2005-06-01
RU2006108524A (ru) 2007-09-27
US7297795B2 (en) 2007-11-20
CN1835923A (zh) 2006-09-20
EP1660453A2 (en) 2006-05-31
IL173456A0 (en) 2006-06-11
CO5670369A2 (es) 2006-08-31
SG145744A1 (en) 2008-09-29
AR045277A1 (es) 2005-10-19
CA2535385A1 (en) 2005-03-03
RU2345069C2 (ru) 2009-01-27
US20080033175A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
BRPI0413667A (pt) Processo para a preparação de 4-amino-3-carbonitrilas de quinolina
SG11201407017WA (en) Site-specific labeling methods and molecules produced thereby
SG11201900947RA (en) Tlr7/8 antagonists and uses thereof
WO2008013454A3 (en) Immunogenic compounds and protein mimics
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
BRPI0508703A (pt) processo para a sìntese de um antagonista de cxcr4
WO2009065508A3 (en) Water-soluble rylene dyes, methods for preparing the same and uses thereof as fluorescent labels for biomolecules
BR0210965A (pt) Conjugado de quelador, complexo de radiometal, radiofármaco, kit para a preparação do mesmo, composto, e, processo para a preparação do mesmo
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
BR0214559A (pt) sais de ácido succìnico do 5,8,14-triazatetraciclo [10.3.1.0<2,11>.0<4,9>]-hexadeca-2(11),3,5,7,9-penteno e suas composições farmacêuticas
WO2011034583A3 (en) Inhibition of endosomal toll-like receptor activation
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
WO2004110976A3 (en) Process for the preparation of aromatic amines
BRPI0517796A (pt) compostos de imidazo[1,2-a]piridina, bem como processo para preparação, composição e uso dos mesmos
WO2012087888A3 (en) Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (g) quinazoline trisodium salt
BRPI0500590A (pt) Processo para a sìntese de compostos de 1,3,4,5-tetraidro-2h-3-benzazepin-2-ona, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
DE60316047D1 (de) Verfahren zur Herstellung von Olanzapine und ein Zwischenprodukt dafür
BRPI0409235A (pt) processo para a produção de sal de amÈnio do ácido 2-hidróxi-4-metiltiobutìrico
AR056805A1 (es) Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
BR0209842A (pt) Processo para a preparação de imipenem
BRPI0407377A (pt) Processo para a preparação de aminoácidos bicìclicos aromáticos e intermediários dos mesmos
BRPI0513807A (pt) sìntese de amidas do ácido 6, 7 - diidro - 5h - imidazo [1, 2-a] imidazol - 3 - sulfÈnico
TH74094A (th) กรรมวิธีสำหรับการเตรียมฟังก์ชันแนลไลเซด 4-อะมิโน-ควินอลีนโดยการไซโคลดีไฮเดรท
BRPI0508213A (pt) monocloridrato de 8-hidroxi-5-[(1r)-1-hidroxi-2[[(1r)-2-(4-metoxifenil)-1-meti letil]amino]etil]-2(1h)-quinolinona na forma cristalina e o processo para sua preparação
WO2001041816A3 (de) Mikropartikel auf basis von asparaginsäure und deren verwendung als mri-kontrastmittel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.